Source comparison
BPC-157 vs Standard Ulcer Treatments: Mechanism and Efficacy Comparison
BPC-157 Upregulates VEGF and bFGF; promotes angiogenesis and epithelial migration 60–80% reduction in 7–14 days (animal models) Potentially superior via improved vascular support Injectable (subcutaneous or intramuscular) Strongest regenerative mechanism but n
This comparison does not assign a generated winner or score.
- BPC-157
- Upregulates VEGF and bFGF; promotes angiogenesis and epithelial migration
- 60–80% reduction in 7–14 days (animal models)
- Potentially superior via improved vascular support
- Injectable (subcutaneous or intramuscular)
- Strongest regenerative mechanism but no human trial data. Works post-injury, not just preventively
- Proton Pump Inhibitors (omeprazole)
- Inhibits H+/K+ ATPase to reduce gastric acid secretion
- 70–85% healing at 8 weeks (human trials)
- Moderate. Relapse common after discontinuation
- Oral (daily)
- Gold standard for acid suppression but doesn't address vascular insufficiency
- H2 Receptor Antagonists (ranitidine)
- Blocks histamine-mediated acid secretion
- 50–70% healing at 8 weeks (human trials)
- Lower than PPIs
- Oral (daily or twice daily)
- Less effective than PPIs; largely replaced in clinical practice
- Prostaglandin Analogs (misoprostol)
- Restores mucosal prostaglandin levels to maintain blood flow
- 60–75% healing at 8 weeks (human trials)
- Good for NSAID-induced ulcers
- Oral (multiple daily doses)
- Effective for NSAID ulcer prevention but significant GI side effects limit use
- Sucralfate
- Forms protective barrier over ulcer; binds bile acids and pepsin
- 60–70% healing at 8 weeks (human trials)
- Minimal. Mechanical protection only
- Useful as adjunct but inferior to acid suppression monotherapy
- The comparison reveals BPC-157's unique position: it's the only agent that actively rebuilds tissue architecture rather than just protecting existing tissue or suppressing acid. PPIs heal ulcers by reducing the caustic environment. BPC-157 heals ulcers by accelerating the biological repair cascade. That mechanistic difference suggests potential combination therapy: a PPI to control acid plus BPC-157 to drive regeneration could theoretically outperform either alone, though no study has tested this.